Results 151 to 160 of about 1,470 (198)
Some of the next articles are maybe not open access.
Neurology, 2019
Autoimmune myasthenia gravis (MG) is a prototypical, antibody-mediated disorder involving fluctuating ocular and generalized skeletal muscle weakness. In over 90% of patients with generalized MG, serum antibodies develop against one of 3 endplate proteins (acetylcholine receptor [AChR], muscle-specific tyrosine kinase [MuSK], and lipoprotein receptor ...
Amanda C, Guidon, Vern C, Juel
openaire +2 more sources
Autoimmune myasthenia gravis (MG) is a prototypical, antibody-mediated disorder involving fluctuating ocular and generalized skeletal muscle weakness. In over 90% of patients with generalized MG, serum antibodies develop against one of 3 endplate proteins (acetylcholine receptor [AChR], muscle-specific tyrosine kinase [MuSK], and lipoprotein receptor ...
Amanda C, Guidon, Vern C, Juel
openaire +2 more sources
Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod
Frontiers in ImmunologyObjectiveWe aimed to explore the efficacy and safety of efgartigimod in patients with refractory immune-mediated necrotizing myopathy (IMNM).MethodsThis open-label pilot observational study included seven patients with refractory IMNM, all of whom received intravenous efgartigimod treatment.
Zhaoxia Wang, Yun Yuan, Yawen Zhao
exaly +4 more sources
Efgartigimod in the treatment of Guillain–Barré syndrome
Journal of NeurologyGuillain-Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which thus may be a promising therapeutic drug for GBS.The two patients presented with postinfectious and acute flaccid paralysis.
Huiqiu Zhang +10 more
openaire +2 more sources
Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases
Trends in Pharmacological Sciences, 2018Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases.
Bayry, Jagadeesh, Kaveri, Srini
openaire +2 more sources
Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases
Immunology LettersMyasthenia gravis (MG) is an autoimmune disease characterized by disrupted neuromuscular synaptic transmission. Efgartigimod, a human Fc receptor antagonist, has been approved for patients with MG. Its potential use for other IgG-mediated neurological autoimmune diseases is unclear.
Lipin Yuan, Rui Pang
exaly +3 more sources